Abstract:The Hippo pathway plays a critical role in organ size control in development. Deregulation of the Hippo pathway leads to drastic enlargement of organs due to increased cell proliferation, inhibition of apoptosis, and dedifferentiation of differentiated cells. Interestingly, deregulation of the Hippo pathway also plays a critical role in tumorigenesis. However, precise roles of the Hippo pathway in tumorigenesis are unclear. By generating genetically defined liver tumor-initiating cells (TICs) with Hippo pathway inactivation or YAP activation, we found that the Hippo pathway unexpectedly mediates a crosstalk between TICs and the immune system. Via cytokines induced by YAP, TICs actively recruit M2 macrophages from as early as the single-cell stage. Elimination of TIC-associated macrophages (TICAMs) abolishes tumorigenesis in a manner dependent on the immune system. Furthermore, YAP activation has been observed in TICs induced by pathologically relevant oncogenes in murine livers and in human hepatocellular carcinoma (HCC) precancerous lesions. These results demonstrate for the first time that macrophages play a decisive role in the survival of single TIC in vivo and provide a proof of principle for TIC elimination by targeting YAP or M2 macrophages. Furthermore, we found that YAP induces leukocyte-specific integrin β2 (ITGB2) expression in cancer cells, thereby promoting cell invasion through the endothelium in a manner mimicking leukocytes. Through independent biochemical purification and a functional screen, we further identified PR/SET domain 4 (PRDM4) as a transcription factor interacting with the WW domains of YAP to mediate ITGB2 expression and cell invasion. Consistently, ITGB2 and PRDM4 mRNA levels are significantly increased in metastatic prostate cancer. In addition, PRDM4 contributes to YAP-induced tumorigenesis, possibly via mediating the expression of other YAP target genes. Our results demonstrate that YAP promotes cell invasion by inducing leukocyte-specific integrin expression and identify PRDM4 as a novel transcription factor for YAP targets. Citation Format: Xiaocan Guo, Huan Liu, Xiaolei Cao, Bin Zhao. The Hippo pathway in cancer [abstract]. In: Proceedings of the AACR Special Conference on the Hippo Pathway: Signaling, Cancer, and Beyond; 2019 May 8-11; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(8_Suppl):Abstract nr IA21.

HERC3 Promotes YAP/TAZ Stability and Tumorigenesis Independently of Its Ubiquitin Ligase Activity.

TEAD Mediates YAP-dependent Gene Induction and Growth Control

ATXN3 promotes prostate cancer progression by stabilizing YAP

Supplement Methods from EIF3H Orchestrates Hippo Pathway–Mediated Oncogenesis Via Catalytic Control of YAP Stability

SET1A-Mediated Mono-Methylation at K342 Regulates YAP Activation by Blocking Its Nuclear Export and Promotes Tumorigenesis.

HERC3 regulates epithelial-mesenchymal transition by directly ubiquitination degradation EIF5A2 and inhibits metastasis of colorectal cancer

Tead Transcription Factors Mediate the Function of Taz in Cell Growth and Epithelial-Mesenchymal Transition

Taz Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and is Inhibited by the Hippo Pathway

YAP/TAZ for cancer therapy: Opportunities and challenges (Review)

Abstract IA21: the Hippo Pathway in Cancer

Integration of Mechanical and Chemical Signals by YAP and TAZ Transcription Coactivators.

Regulation of TP73 Transcription by Hippo-YAP Signaling.

TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin

YAP inhibits ERα and ER+ breast cancer growth by disrupting a TEAD-ERα signaling axis

MAML1/2 promote YAP/TAZ nuclear localization and tumorigenesis

Abstract 4516: Inhibiting YAP activity in cancers by targeted degradation of TEAD

Yap and Taz Take Center Stage in Cancer

The Hippo Tumor Pathway Promotes Taz Degradation By Phosphorylating A Phosphodegron And Recruiting The Scf Beta-Trcp E3 Ligase

YAP/TAZ: a promising target for squamous cell carcinoma treatment

SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway

Human telomerase reverse transcriptase is a novel target of Hippo-YAP pathway